A Real-World Study of Oral Antihyperglycemic Agents as Compared With Basal Insulin in Hospitalized Patients With Type 2 Diabetes
Authors' conclusion
The use of OADs in the hospital appeared to be safe and effective for management of hyperglycemia among patients with type 2 diabetes and a lower burden of comorbidities.
Study context
- Population
- Hospitalized patients with T2D, 3 health care systems in the United States and Israel, 2010–2019
- Participants
- 79,047 patients
- Exposure
- OAD vs basal insulin vs OAD + basal insulin
- Outcome
- Inpatient target glycemia: mean blood glucose 80 to 180 mg/dL and no hypoglycemia (<70 mg/dL)
Methodological detailsmulticentre, inverse probability weighting
- Multicentre
- Inverse probability weighting
Main finding
As reported in the abstract
Target glycemia
Each group vs basalOdds ratio (95% CI)
OAD
2.07(1.85–2.31)
OAD + basal
0.99(0.95–1.04)
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| MortalityOADvs Basal | 0.16 (0.11–0.24) | |
| MortalityOAD + basalvs Basal | 0.34 (0.23–0.49) | |
| 0.10.31310Odds ratio (log scale) |
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| HypoglycemiaOADvs Basal | 0.54 (0.46–0.62) | |
| 0.512Odds ratio (log scale) |
Hypoglycemia
- Patients treated with sulfonylureas had higher rates of hypoglycemia
Lactic acidosis
- Metformin monotherapy not associated with higher risk of lactic acidosis
Original publication
A Real-World Study of Oral Antihyperglycemic Agents as Compared With Basal Insulin in Hospitalized Patients With Type 2 Diabetes. Endocr Pract. Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →